Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection-Reference-Cited by-同舟云学术

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

Published:2018-02-13 Issue:5 Volume:118 Page:679-697
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Viala Marie,Vinches Marie,Alexandre Marie,Mollevi Caroline,Durigova Anna,Hayaoui Nadia,Homicsko Krisztian,Cuenant Alice,Gongora Céline,Gianni Luca,Tosi Diego

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2017473.pdf

Reference147 articles.

1. Agus DB (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23: 2534–2543.

2. Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI (2007) Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25: 675–681.

3. Alfonso S, Díaz RM, de la Torre A, Santiesteban E, Aguirre F, Pérez K, Rodríguez JL, Barroso MC, Hernández AM, Toledo D, Gabri MR, Alonso DF, Viada C, Gómez RE, Pestana E, Suarez E, Vázquez AM, Perez R, Macías A (2007) 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 6: 1847–1852.

4. Alfonso S, Valdes-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernandez M, Viada CE, Mendoza IC, Guerra PP, Garcia E, Ortiz RA, de la Torre AV, Cepeda M, Perez K, Chong E, Hernandez AM, Toledo D, Gonzalez Z, Mazorra Z, Crombet T, Perez R, Vazquez AM, Macias AE (2014) A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 20: 3660–3671.

5. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372: 311–319.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden;Chemotherapy;2024-04-27

2. Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms;Journal of Pharmacokinetics and Pharmacodynamics;2023-11-12

3. Utilization of genetic information for medicines development and equitable benefit sharing;Frontiers in Genetics;2023-06-14

4. 89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC;European Journal of Nuclear Medicine and Molecular Imaging;2023-03-02

5. Drug delivery improvements to enable a flexible care setting for monoclonal antibody medications in oncology - Analogue-based decision framework;Expert Opinion on Drug Delivery;2023-02-28